Windtree Therapeutics, Inc. (WINT)
Biological Products, (No Diagnostic Substances) · market cap $613,500
Research and calibrated estimates, not financial advice — verify before acting.
No upcoming catalysts in our calendar.
| Asset | Phase | Indication |
|---|---|---|
| Istaroxime | Phase 2 | Cardiogenic Shock |
| Lucinactant | Phase 2 | Acute Hypoxemic Respiratory Failure |
| Rostafuroxin | Phase 2 | Hypertension |
| Lucinactant for Inhalation | Phase 2 | Respiratory Distress Syndrome |
| Lucinactant delivered via investigational delivery device | Phase 2 | Respiratory Distress Syndrome |
| Lucinactant first | Phase 2 | Cystic Fibrosis |
Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
- SEC filings — EDGAR filings for WINT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.